Fulgent Genetics, Inc. (FLGT) Therapeutic Development — Interest Expense Nonoperating — Quarterly & Annual

Screener

Other segment segments

Laboratory Services

$17K+21.4%

Similar metrics at other companies

PCYOWater And Wastewater Resource Development — Interest Expense Nonoperating

$33K-10.8%

GKOSDevelopment And Commercialization Of Ophthalmic Therapies — Interest Expense Nonoperating

-$1.46M-227%

BRORetail — Interest Expense Nonoperating

$5M-66.7%

ELACommercial — Interest Expense Nonoperating

$40.39K-22.7%

ELAConsumer — Interest Expense Nonoperating

$38.39K-29.0%

SPAIOther — Interest Expense Nonoperating

$1.34K-1.1%

Other financials

Income statement

Revenue$71.1M-3.2%

Gross profit$21.5M-24.2%

Operating income-$34.6M-74.9%

Net income-$24.8M-115%

EPS (diluted)-$0.80-116%

Balance sheet

Cash & equivalents$23.4M-65.2%

Total debt$8.2M+40.5%

Total equity$1.0B-6.9%

Total assets$1.2B-4.1%

Cash flow

Operating cash flow$7.1M+260%

CapEx$5.2M+10.3%

Free cash flow$1.9M+121%

Valuation

Market cap$526.64M-16.5%

Enterprise value$511.45M-6.7%

P/S1.6×-0.4×

Profitability

Gross margin38.7%-0.1pp

Operating margin-33.1%+17.4pp

Net margin-23%+43.3pp

FCF margin-36.9%—

Returns & leverage

Return on equity-6.8%+48.2pp

Debt / equity0×0.0×

Current ratio5.3×-1.0×

Where this comes from

Reported directly by Fulgent Genetics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:InterestExpenseNonoperating.

The source filing: Fulgent Genetics, Inc.’s 10-Q, filed May 1, 2026.

Filed: May 1, 2026, 7:08 AM EDT
Fiscal quarter: Q1 FY2026
Calendar quarter: Q1 2026
Accession: 0001193125-26-199065

Line item	Three Months Ended March 31, 2026	Three Months Ended March 31, 2025
Laboratory services
Interest income	$8,651	$8,018
Interest expense	(17)	(14)
Therapeutic development
Interest income	—	—
Interest expense	—	—
Total	$8,634	$8,004

Item 1. Financial Statements.

FAQ

What is Fulgent Genetics, Inc.'s therapeutic development — interest expense nonoperating?: Fulgent Genetics, Inc. (FLGT) reported therapeutic development — interest expense nonoperating of $0 in Q1 2026.
What does therapeutic development — interest expense nonoperating mean?: This represents interest costs incurred on debt or financing arrangements that are not related to the core operating activities of the therapeutic development segment. It is used to assess the impact of the segment's financing structure on its overall financial health.

Ask your AI about Fulgent Genetics, Inc.'s therapeutic development — interest expense nonoperating.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI

Harbor at dusk